We have 5 of 18 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Cancer of unknown primary (CUP) is a heterogeneous group of metastatic malignancies in which the primary site remains unidentified despite appropriate diagnostic evaluation. Historically, most patients with unfavorable CUP have received empirical platinum-based chemotherapy, but recent advances in immune checkpoint inh...
The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
